Integrated Report

For viewing Size: A3[PDF]

For Printing Size: A4[PDF]

Download individually

Introduction

• 02_Corporate Message[PDF]
• 03_Messages from Employees[PDF]
• 05_Opening Feature:Importance of Women’s Healthcare and Social Issues[PDF]

Value Creation Story

• 13_History of Value Creation[PDF]
• 17_At a Glance[PDF]
• 19_The Foundation for Our Path Forward[PDF]
• 21_Message from the Chairman[PDF]
• 23_Message from the President[PDF]
• 27_Value Creation Process[PDF]
• 29_Capital and Strengths[PDF]
• 31_Current Business Climate[PDF]
• 33_Material Issues[PDF]
• 37_Featured Dialogue:The Importance of Women’s Healthcare and Addressing Social Issues[PDF]

Explanation of Strategy

• 41_ASKA Pharmaceutical Holdings’ Medium-Term Management Plan 2025[PDF]
• 43_ASKA Pharmaceutical[PDF]
• 48_Ha Tay Pharmaceutical Joint Stock Company[PDF]
• 49_ASKA Animal Health[PDF]
• 51_ASKA Pharma Medical[PDF]
• 53_Financial and Capital Strategy[PDF]
• 57_Manufactured Capital and Intellectual Capital Strategies[PDF]
• 62_Natural Capital Strategy[PDF]
• 67_Social Capital Strategy[PDF]
• 71_Human Capital Strategy[PDF]

Foundation for Value Creation

• 79_Roundtable Discussion on Corporate Governance[PDF]
• 83_Board Members and Corporate Officers[PDF]
• 85_Corporate Governance[PDF]
• 93_Compliance[PDF]
• 94_Risk Management[PDF]

Data Section

• 95_11-Year Summary of Consolidated Financial Results[PDF]
• 97_Initiatives/External Evaluation/Third-Party Opinion[PDF]
• 98_Company Information/Shareholder Information[PDF]